Annual Updates on Labeling Changes for NDAs and ANDAs Regarding Nonprescription Medications
On March 2024, the FDA is releasing a draft guidance for industry that, once finalized, will offer suggestions to holders of approved New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) for nonprescription drug products on how to document minor labeling changes in their subsequent annual reports.